Uni-Bio Science Group Limited：2021 Annual Results

HONG KONG SAR – EQS Newswire – 22 March 2022 – A totally built-in biopharmaceutical firm – Uni-Bio Science Group Restricted (“Uni-Bio Science”, along with its subsidiaries known as the “Group”, inventory code: 0690.HK), is happy to announce its annual outcomes for the 12 months ended 31 December 2021 (the “12 months”), in addition to its comparative figures for the 12 months ended 31 December 2020 (“2020”).

Throughout the 12 months, the Group achieved a spectrum of accomplishments, for each of its marketed merchandise and modern biologics. The important thing highlights embrace:

1. Throughout the 12 months, the Group achieved a report excessive turnover of HK$ 353.4 million, representing a noticeable improve of 69.3% year-on-year (“YoY”). The income development was primarily attributable to the robust rebound of the Group’s core merchandise. Gross sales of GeneTime^® and GeneSoft^® had absolutely recovered and exceeded the pre-COVID-19 stage, registered a rise of 24.3% and 14.8% YoY respectively. The Group began the mass manufacturing of Boshutai^® and the gross sales of Boshutai^® met the Group’s expectation.
2. Throughout the 12 months, the medical trial for the 2nd Technology liquid kind Uni-PTH had been efficiently accomplished and the Group has deliberate to use for New Drug Utility (“NDA”) in 2022. At the moment, the Group is in preparation for information amassing for the event of the third Technology oral kind Uni-PTH.
3. Medical trial-related works for Uni-GLP-1 liquid formulation have been launched throughout the 12 months as deliberate and the Group goes to speed up additional medical work in 2022. Furthermore, the Group is in technique of creating oral kind Uni-GLP-1 to develop the worth of the product and supply comfort to customers.
4. The Group developed a strategic partnership with DotBio Pte. Ltd. (“DotBio”) to co-develop next-generation best-in-class compounds in ophthalmology and different potential therapeutic areas. Beneath the settlement, DotBio’s Hong Kong subsidiary, DotBioHK, is chargeable for producing a number of multi-valent and/or bi-specific stabilized and humanized single-domain antibody candidates for numerous targets utilizing DotBio’s proprietary DotBody know-how. The Group is chargeable for chemical manufacturing management (CMC), investigation New Drug (IND) submission, medical trial and commercialization.
5. The Group fashioned a strategic partnership with Alephoson Biopharmaceuticals Ltd. (“Alephoson”) to discover new know-how in retinal ailments in addition to to beat the constraints of intravitreal injection remedy. Forming partnerships and alliances with Alephoson not solely aligns with the Group’s long-term improvement plan of increasing the pipeline of next-generation medication, however it additionally diversifies formulation selections of the Group’s marketed and pipeline merchandise.
6. Throughout the 12 months, the Group collaborated with Nano and Superior Supplies Institute (“NAMI”) to co-develop an modern formulation of rhEGF (recombinant human epidermal development issue) merchandise together with GeneTime®. Leveraging NAMI’s modern materials know-how, the Group can diversify the formulation of rhEGF merchandise and probably develop software scope sooner or later.

Annual Outcomes

In 2021, the Group recorded a turnover of HK$353.4 million, representing a big improve of roughly 69.3% year-on-year (2020: HK$208.8 million). The rise in turnover was primarily attributable to the spectacular gross sales development of EGF merchandise. Throughout the 12 months, turnover generated from GeneTime^® reached HK$170.5 million, representing a big improve of 24.3% from roughly HK$137.2 million in 2020. The exceptional turnover development was primarily as a result of robust restoration from hospital gross sales in addition to the extra turnover from the digital advertising and pharmaceutical e-commerce platforms. GeneSoft^® recorded a rise in turnover from roughly HK$31.6 million to HK$36.3 million, representing a rise of 14.8%. Development in gross sales of GeneSoft^® was attributed to the restoration from hospital gross sales in addition to the efforts of the Group’s direct gross sales group. 2021 was the primary 12 months for Boshutai^®‘s commercialization and the turnover of Boshutai^® was roughly HK$4.5 million. The remaining gross sales of HK$142.2 million is attributed from Pinup^®. Though there was an robust quantity development for Pinup^® throughout the 12 months, the lower in pricing as a result of centralized procurement has scale back the general profitability of the product.

Gross revenue was HK$277.0 million, representing a rise of 53.0% as in contrast with roughly HK$181.1 million in 2020. Gross revenue margin decreased to 78.4% from 86.7% in 2020, principally resulting from Pinup^®‘s value concession for the nationwide centralized procurement. The Group continued its strict management on the whole and administrative bills, which solely accounted for 13.4% of turnover in 2021 as in contrast with 17.2% in 2020. The promoting and distribution expense for the 12 months additionally decreased to 52.5% of turnover from 69.7% in 2020. The R&D bills elevated by 23.3% YoY to HK$50.2 million because the Group continued to develop new merchandise. Working loss for the 12 months was HK$20.0 million as heavy funding in R&D continued. Nonetheless, the working loss was considerably lowered from HK$70.9 million in 2020. In 2021, the Group recorded a lack of HK$19.6 million (2020: lack of HK$71.3 million), with a primary loss per share of HK$0.31 cents (2020 primary loss per share HK$1.11 cents).

Prospects

The healthcare market in China has been burgeoning. The expansion is pushed by the growing growing older inhabitants, higher social medical health insurance insurance policies in addition to authorities regulatory reforms which promote industrial innovation and streamline the brand new drug approval course of. Using on the favorable authorities insurance policies and market atmosphere, the Group believes that it will propel ahead and drive additional enterprise development.

To seize the brand new alternatives in medical cosmetology, purposeful skincare and high-end skincare market, the Group fashioned joint cooperation and funding with International Cosmetics (China) Firm Ltd. (“International Group”) to develop new aggressive and efficient skincare uncooked supplies, for use broadly in quite a lot of areas together with medical cosmetology, purposeful skincare and high-end skincare. Leveraging on International Group’s experience in day by day cosmetics and its well-established associate community, along with the Group’s in depth expertise in pharmaceutical R&D, this collaboration has laid a robust basis for the 2 events to faucet into the huge purposeful skincare and upstream uncooked materials market. It’s anticipated that new medical magnificence, purposeful and high-end skincare merchandise underneath this collaboration might be launched as early as the top of 2022.

Trying ahead, Mr. Kingsley Leung, Chairman of Uni-Bio Science stated, “We proceed to concentrate on all-round analysis innovation of patented biologics. Since 2021, the Group had fashioned a stronger partnership with Alephoson and DotBio to co-develop next-generation best-in-class compounds for sufferers with retinal ailments and different potential therapeutic areas. The collaboration goes to additional advance affected person care with remedy alternate options and discover additional functions within the ophthalmology and dermatology industries. The Group can be going to speed up the medical technique of Uni-GLP-1 and start preparation for the commercialization of each Uni-PTH and Uni-GLP-1.”

By way of the Group’s marketed merchandise, Mr. Leung added, “We’ve got deliberate forward for its manufacturing capability enlargement years in the past. Manufacturing of Boshutai^® tablets, which launched in 2021, might be taken care of by the Group’s strategic associate, Suzhou Yingli in 2022 with greater than ten occasions bigger provide capability. The opposite strategic associate Sinopharm Wiqida might be accountable for uncooked materials Acarbose lively ingredient (API) registration and manufacturing; the registration is predicted to finish in 2022. All these would facilitate Boshutai^® to win the bid of the approaching nationwide centralized procurement in 2022. The Group had additionally determined to relocate the manufacturing web site of its EGF merchandise to Dongguan in an effort to meet up with the rising order guide of GeneSoft^® and GeneTime^®, in addition to develop the product line of our EGF product collection. The brand new manufacturing base is predicted to start operation in 2025.”

The Group believes that the aforementioned methods will additional push ahead its product R&D with larger effectivity, widen its product functions, in order to speed up the commercialization of its modern medication, and at last generate fruitful and sustainable returns for its shareholders.

About Uni-Bio Science Group Restricted

Uni-Bio Science Group Restricted is principally engaged within the analysis and improvement, manufacture and distribution of pharmaceutical merchandise. The analysis and improvement centre is absolutely outfitted with a whole system for the event of genetically-engineered merchandise with a pilot plant check base which is in keeping with NMPA necessities. The Group additionally has two GMP manufacturing bases in Beijing and Shenzhen. The Group additionally has a extremely environment friendly commercialization platform and advertising community. The Group focuses on the event of novel remedies and modern medication addressing the therapeutic areas of endocrine reminiscent of diabetes and osteoporosis, ophthalmology and dermatology.

Uni-Bio Science Group Restricted was listed on the Essential Board of the Hong Kong Inventory Change on November 12, 2001. Inventory code: 0690.

#UniBioScienceGroup

The issuer is solely chargeable for the content material of this announcement.